Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00463723
Status:
TERMINATED
Last Update Posted:
2007-04-20
First Post:
2007-04-18
Brief Title:
Topical FK506 Tacrolimus for Prevention of Immune Reactions Following Penetrating Keratoplasty
Sponsor:
University Hospital Freiburg
Organization:
University Hospital Freiburg
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
1999-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions Steroids are known to yield good results but exert a wide range of side effects The efficacy of topial FK506 in preventing immune reactions has already been demonstrated experimentally FK506 an IL-2-inhibitor like Cyclosporin A CSA is known to be approximately 100 fold more potent than CSA Aim of the study In this study the efficacy and safety of topical FK506 will be compared to our standard treatment ie steroids after penetrating normal-risk keratoplasty
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None